glp 1 drugs for parkinson's disease GLP-1 does not slow progression in phase 3 study GLP-1 and Parkinson's Disease: Research,

#GLP1 #HealthyLiving

This article explores the science behind these agents.

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

Regulates appetite and blood sugar

People on GLP-1s had slightly higher risks of osteoporosis and gout than similar people not taking these drugs

Here's what to expect and practical steps to help maintain your progress.